American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th(DSM-IV)Washington (DC): American Psychiatric Association, 1994.
4.
ChinKM, ChannickRN, RubinLJ. Is methamphetamine use associated with idiopathic pulmonary arterial hypertension?Chest, 130:1657–1663. 2006.
5.
Concerta Product Monograph. Janssen-Orto Inc.www.janssen-ortho.com/JOI/pdf_files/concerta_E.pdf/. 2010 January 13.
6.
LeeSL, WangWW, MooreBJ, FanburgBL. Dual effect of serotonin on growth of bovine pulmonary artery smooth muscle cells in culture. Circ Res, 68:1362–1368. 1991
7.
LewmanLV. Fatal pulmonary hypertension from intravenous injection of methylphenidate (Ritalin) tablets. Hum Pathol, 3:67–70. 1972.
8.
LundquestDE, YoungWK, EdlandJF. Maternal death associated with intravenous methylphenidate (Ritalin) and pentazocine (Talwin) abuse. J Forensic Sci, 32:798–801. 1987.
9.
MacLeanMR. Pulmonary hypertension and the serotonin hypothesis: Where are we now?Int J Clin Pract Suppl, 156:27–31. 2007.
10.
MarcosE, FadelE, SanchezO, HumbertM, DartevelleP, SimonneauG, HamonM, AdnotS, EddahibiS. Serotonin-induced smooth muscle hyperplasia in various forms of human pulmonary hypertension. Circ Res, 94:1263–1270. 2004.
11.
NaranjoCA, BustoU, SellersEM, SandorP, RuizI, RobertsEA, JanecekE, DomecqC, GreenblattDJ. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther, 30:239–245. 1981.
12.
NauserTD, StitesSW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician, 63:1789–1798. 2001.
13.
NissenSE. ADHD drugs and cardiovascular risk. NEJM, 354:1445–1448. 2006.
14.
RichS, RubinL, WalkerAM, SchneeweissS, AbenhaimL. Anorexigens and pulmonary hypertension in the United States: Results from the Surveillance of North American Pulmonary Hypertension. Chest, 117:870–874. 2000.
15.
RothmanRB, AyestasMA, DerschCM, BaumannMH. Aminorex, fenfluramine, and chlorphentermine are serotonin transporter substrates. Implications for primary pulmonary hypertension. Circulation, 100:869–875. 1999.
16.
SalviSS. Alpha1-adrenergic hypothesis for pulmonary hypertension. Chest, 115:1708–1719. 1999.
17.
van WolferenSA, Vonk NoordegraafA, BoonstraA, PostmusPE. Pulmonary arterial hypertension due to the use of amphetamines as drugs or doping. Ned Tijdschr Geneeskd, 149:1283–1288. 2005.
18.
WillersED, NewmanJH. New risks for pulmonary hypertension: Need for a large epidemiologic study. Chest, 130:1633–1635. 2006.
19.
WintersteinAG, GerhardT, ShusterJ, JohnsonM, ZitoJM, SaidiA. Cardiac safety of central nervous system stimulants in children and adolescents with attention-deficit/hyperactivity disorder. Pediatrics, 120:1494–1501. 2007.
20.
ZolkowskaD, RothmanRB, BaumannMH. Amphetamine analogs increase plasma serotonin: Implications for cardiac and pulmonary disease. J Pharmacol Exp Ther, 318:604–610. 2006.
